Showing 5271-5280 of 5771 results for "".
- Novartis Issues Summary Financial Information for the Alcon Eye Care Business Ahead of Shareholder Votehttps://modernod.com/news/novartis-issues-summary-financial-information-for-the-alcon-eye-care-business-ahead-of-shareholder-vote/2476260/Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon at the Novartis Annual General Meeting of Shareholders (AGM) on February 28, 2019. The issuance of the short form fi
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multicenter Clinical Trial for Treating Dry AMDhttps://modernod.com/news/lumithera-receives-notice-of-award-for-2-5-million-national-eye-institute-grant-to-support-u-s-multicenter-clinical-trial-for-treating-dry-amd/2476262/LumiThera announced that it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi
- Nidek Launches Upgraded AngioScan OCT-Angiography Softwarehttps://modernod.com/news/nidek-launches-upgraded-angioscan-oct-angiography-software/2476265/Nidek has announced the launch of new AngioScan upgraded OCT-Angiography software that enables visualization of retinal and choroidal microvasculature and blood flow using the RS-3000 Advance 2 OCT device. The
- FDA Approves Bausch + Lomb’s Lotemax SM For The Treatment Of Postoperative Inflammation And Painhttps://modernod.com/news/fda-approves-bausch-lombs-lotemax-sm-for-the-treatment-of-postoperative-inflammation-and-pain/2476267/Bausch + Lomb announced that the FDA has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery. Compared to Lotemax Gel 0.5%, Lotemax SM delivers a submicron particle size for faste
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with J&J’s Janssenhttps://modernod.com/news/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-jjs-janssen/2476272/Morphic Therapeutic announced that it has entered into a research and development collaboration with Johnson & Johnson’s subsidiary Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson &a
- RightEye Introduces Functional Vision EyeQ Automated Testhttps://modernod.com/news/righteye-introduces-functional-vision-eyeq-automated-test/2476278/RightEye announced the launch of Functional Vision EyeQ, a first-of-its kind automated test that allows optometrists to quickly and objectively identify functional vision issues that affect a host of everyday activiti
- AbbVie’s Humira (Adalimumab) Approved by Health Canada to Treat Pediatric Patients with Chronic Noninfectious Anterior Uveitishttps://modernod.com/news/abbvies-humira-adalimumab-approved-by-health-canada-to-treat-pediatric-patients-with-chronic-noninfectious-anterior-uveitis/2476279/AbbVie announced that Health Canada has approved Humira (adalimumab) for the treatment of chronic noninfectious anterior uveitis in pediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropr
- Bruder Introduces Hygienic Eyelid Solutionhttps://modernod.com/news/bruder-introduces-hygienic-eyelid-solution/2476280/Bruder Healthcare announced the immediate availability of Bruder Hygienic Eyelid Solution, a 0.2% pure hypochlorous acid solution that’s safe for daily, long-term use. This solution contains no alcohol, oil, sulfates,